ArticleArchives of orthopaedic and trauma surgery2026
Preoperative NarxCare overdose risk scores greater than 100 are associated with worse PROMs improvements and dissatisfaction after primary THA.
Article in Archives of orthopaedic and trauma surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe NarxCare Overdose Risk Score (ORS) is a weighted measure of patient-specific prescription drug use. In patients undergoing primary total hip arthroplasty (THA), this study aimed to evaluate (1) the trend of the ORS from preoperative to 1-year postoperatively, and (2) the association of preoperative ORS with achievement of clinically meaningful improvements in patient reported outcome measures (PROMs), and satisfaction at 1-year.
methodsAll patients who underwent primary unilateral elective THA at a USA tertiary healthcare system from January 2016-December 2022 were eligible. Patients with incomplete PROMs or missing baseline NarxCare ORS were excluded, leading to the inclusion of 5,424 patients. Multivariable regression models were used to assess the association between ORS and 1-year PROMs, including achievement of the minimum clinically important difference (MCID) and Patient Acceptable Symptom State (PASS) for the Hip Disability and Osteoarthritis Outcome Score (HOOS) subdomain scores, as well as satisfaction.
resultsPreoperatively, 46.1% (n = 2501) had a NarxCare ORS of 0, 24.6% (n = 1336) had scores between 100 and 199, and 16.2% (n = 876) in the 200-299 range. After adjusting for confounding variables, a preoperative ORS of 100-199 was associated with failure to achieve MCID in HOOS Pain (OR 1.91;CI 1.32-2.77;p = 0.001), and HOOS JR (OR 1.54;1.10-2.15;p = 0.012). Preoperative ORS of 100-199 was also associated with failure to reach PASS threshold in HOOS Pain (OR 1.45;1.23-1.71;p < 0.001), PS (OR 1.47;1.22-1.75;p < 0.001) and JR (OR 1.26;1.08-1.49;p = 0.004), with the odds of failure continually increasing as the ORS increases. Patients with a preoperative ORS of 100-199 were 58% more likely to be dissatisfied at 1-year (OR 1.58;1.26-1.99;p < 0.001) compared to prescription drug use naïve patients.
conclusionsIncreasing preoperative NarxCare ORS, a measure of prescription drug use, is inversely associated with patient perceived improvement after THA. An ORS of just 100 may significantly decrease the chances of clinically meaningful improvements in hip pain and function, as well as satisfaction at 1-year. A multidisciplinary approach is warranted to mitigate the detrimental effects of sedatives, opioids, or stimulant drug use and surgeons may use this easily accessible score to guide a patient centered discussion regarding postoperative improvements. LEVEL OF EVIDENCE: III.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.